-
Mashup Score: 1Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era - 2 month(s) ago
Two articles this week focus on Erdheim-Chester disease (ECD), a rare histiocytosis that mainly affects adults. Clonal somatic mutations primarily involving pro
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives - 3 month(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
RT @BloodAdvances: Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives https://t.co/ofswy7k24W #commenta…
-
-
Mashup Score: 4Peripheral T-cell lymphoma: Are all patients high-risk? - 4 month(s) ago
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell neoplasms that represent approximately 10% of all non-Hodgkin Lymphoma (NHL). Outc
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrAlbertoLG: Peripheral T-cell lymphoma: Are all patients high-risk? https://t.co/4He7mgnpVz
-
-
Mashup Score: 34Long-term outcomes following CAR T cell therapy: what we know so far - Nature Reviews Clinical Oncology - 6 month(s) ago
Chimeric antigen receptor (CAR) T cells have dramatically improved the outcomes of patients with certain relapsed and/or refractory haematological malignancies. Owing to the promising short-term survival outcomes achieved, long-term data on both safety and survival are becoming increasingly relevant. In this Review, the authors describe the available long-term follow-up data from early studies…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @SCTNB: Long-term outcomes following CAR T cell therapy: what we know so far | Nature Reviews Clinical Oncology https://t.co/dNEWwMZ95w
-
-
Mashup Score: 3German Lymphoma Alliance - 8 month(s) ago
The clinical course of mantle cell lymphoma (MCL) is highly variable. Lower age, better performance status, lower serum lactate-dehydrogenase (LDH) activity, and lower white blood cell (WBC) count at first diagnosis have been shown to be associated with longer progression-free and overall survival in patients with MCL suitable for moderately intensive chemotherapy. Furthermore, the tumour cell proliferation rate Ki-67 index has been identified as strong prognostic marker additional to clinical patient
Source: www.german-lymphoma-alliance.deCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @HematoRules: @MSubklewe #ITC23 ➡️ CAR-HEMATOTOX … great tool ✅ https://t.co/bTlC7CITQY ➡️ Antibiotics and #ICATH … interesting relati…
-
-
Mashup Score: 0Sign the Petition - 9 month(s) ago
Eliminate ABIMs MOC requirement
Source: www.change.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Eliminate ABIMs MOC requirement - Sign the Petition! https://t.co/Vl67lxEFiz via @Change
-
-
Mashup Score: 0Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era - 9 month(s) ago
Two articles this week focus on Erdheim-Chester disease (ECD), a rare histiocytosis that mainly affects adults. Clonal somatic mutations primarily involving pro
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era | Blood | American Society of Hematology https://t.co/rDoRSG3EKm
-
-
Mashup Score: 8Transplant in AML with measurable residual disease: proceed or defer? - 11 month(s) ago
Abstract. Allogeneic stem cell transplantation plays a central role in the management of fit adults with high-risk acute myeloid leukemia (AML) in first complet
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @smbenlazar: Transplant in #AML with measurable residual disease: proceed or defer? https://t.co/MM0n7I1BaX https://t.co/CDYNtSYVS8
-
-
Mashup Score: 2How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy - 1 year(s) ago
Edited by Associate Editor Robert Zeiser, this How I Treat series focuses on post–allogeneic transplant management of high-risk patients. These patients are at
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @albertomussetti: How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy https://t.co/yNbTaiLiNm
-
-
Mashup Score: 1U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes - 1 year(s) ago
Key Points. Hemolysis in MDS is nonimmune, relates to inferior survival trends in low-risk disease, and lower response to erythroid stimulating agentsU2AF1 and
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ZaidAR_MD: U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes https://t.co/xBDsbbo1jD
-
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era | Blood | American Society of Hematology https://t.co/rDoRSG3EKm